Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum TELESTA THERAPEUTICS INC T.TST

"Telesta Therapeutics Inc is a biopharmaceutical company. The Company is engaged in the research, development, manufacturing and commercialization of human health products and technologies."

TSX:TST - Post Discussion

TELESTA THERAPEUTICS INC > How many patients required...
View:
Post by givmeabrake on Sep 27, 2015 6:44pm

How many patients required...

https://www.ncbi.nlm.nih.gov/pubmed/15784083

Clinical trials in urology: how many patients are required to achieve statistically significant results?

Abstract

Comment by DryBones on Sep 28, 2015 1:04am
Gimebrake- thanks for that article it answers some important questions- but leaves me with others. "Generally, the smaller the clinically relevant differences in efficacy between treatments, the more patients are required, to provide sufficient statistical power and meaningful clinical results."   Okay that is clear.  It expains why we can go in with so few trial numbers ...more  
Comment by FarmaBoy on Sep 28, 2015 5:39am
Randomization of the patients at baseline (before study begins) should ensure that baseline characteristics between the two arms are similar and representative of the population as a whole.  i.e. number of patients between 50 and 70 y.o should be similar, number of patients at CIS tumour stage should be similar, number of patients of certain ethnicities should be similar etc. between the two ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities